Bessemer Group
MNTA

Bessemer Group’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Bessemer Group’s Portfolio MNTA Stock Details MNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-121
Closed -$3K – 1783
2015
Q2 		$3K Buy
+121
New +$2.41K ﹤0.01% 1430

Other funds holding MNTA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return

Bessemer Group's MNTA Position: Q3 2015 in Review

Bessemer Group sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q3 2015, closing a stake of 121 shares — an estimated $3K sold.

Bessemer Group first reported a position in MNTA in Q2 2015 and held it in 1 quarter. The position peaked at $3K in Q2 2015. 156 funds tracked by Wall St. Rank hold MNTA as of Q3 2015.

  • Bessemer Group reported no remaining Momenta Pharmaceuticals, Inc. position as of Q3 2015 after selling out during the quarter.
  • Bessemer Group sold 121 Momenta Pharmaceuticals, Inc. shares in Q3 2015, an estimated $3K.
  • Bessemer Group first reported a position in Momenta Pharmaceuticals, Inc. in Q2 2015 and held it in 1 quarter.
  • Bessemer Group's Momenta Pharmaceuticals, Inc. position peaked at $3K in Q2 2015.
  • 156 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q3 2015.

Based on Bessemer Group's 13F filing for Q3 2015, filed 16 Nov 2015.